2/5/2007

Two biotechs are awaiting FDA approval this year for products that could challenge King Pharmaceuticals' control of the market for thrombin drugs used in surgery. Omrix BioPharmaceuticals created thrombin based on human plasma and ZymoGenetics developed a synthetic form.

Full Story:
CNNMoney

Related Summaries